Live Breaking News & Updates on Amneal Pharmaceuticals Company Profile

Stay updated with breaking news from Amneal pharmaceuticals company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Amneal Pharmaceuticals (NYSE:AMRX) Updates FY 2023 Earnings Guidance

Amneal Pharmaceuticals (NYSE:AMRX) Updates FY 2023 Earnings Guidance
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Switzerland , Swiss , Piper-sandler , Swiss-national-bank , Amneal-pharmaceuticals , Amneal-pharmaceuticals-inc , Barclays , Institutional-trading-of-amneal-pharmaceuticals , Panagora-asset-management-inc , York-mellon-corp , Amneal-pharmaceuticals-company-profile , Metlife-investment-management

Amneal Pharmaceuticals (NYSE:AMRX) Issues FY 2023 Earnings Guidance

Amneal Pharmaceuticals (NYSE:AMRX – Get Free Report) issued an update on its FY 2023 earnings guidance on Friday morning. The company provided EPS guidance of $0.45-$0.55 for the period, compared to the consensus EPS estimate of $0.47. The company issued revenue guidance of $2.30 billion-$2.40 billion, compared to the consensus revenue estimate of $2.32 billion. […] ....

Piper-sandler , Barclays , Amneal-pharmaceuticals-price-performance , Amneal-pharmaceuticals-company-profile , Neuberger-berman-group , Amneal-pharmaceuticals-inc , Blackrock-inc , Vanguard-group-inc , Amneal-pharmaceuticals , Institutional-trading-of-amneal-pharmaceuticals , Morgan-stanley , Millennium-management

Amneal Pharmaceuticals (NYSE:AMRX) Price Target Increased to $5.00 by Analysts at Barclays

Amneal Pharmaceuticals (NYSE:AMRX – Get Free Report) had its price objective raised by stock analysts at Barclays from $4.00 to $5.00 in a research report issued on Friday, FlyOnTheWall reports. Barclays‘s price objective indicates a potential upside of 21.65% from the stock’s current price. A number of other brokerages have also weighed in on AMRX. […] ....

Switzerland , Swiss , Piper-sandler , Barclays , York-mellon-corp , Amneal-pharmaceuticals-trading , Panagora-asset-management-inc , News-ratings-for-amneal-pharmaceuticals-daily , Metlife-investment-management , Amneal-pharmaceuticals , Institutional-trading-of-amneal-pharmaceuticals , Blackrock-inc

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Receives $3.60 Consensus PT from Analysts

Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Rating) has received a consensus rating of “Moderate Buy” from the four analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokers that […] ....

Amneal-pharmaceuticals-company-profile , Neuberger-berman-group , Amneal-pharmaceuticals-stock-performance , Blackrock-inc , Goldman-sachs-group , Millennium-management , Amneal-pharmaceuticals-inc , News-ratings-for-amneal-pharmaceuticals-daily , Vanguard-group-inc , Morgan-stanley , Amneal-pharmaceuticals

Amneal Pharmaceuticals (NYSE:AMRX) Shares Up 4.8%

Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Rating) shot up 4.8% on Friday . The company traded as high as $2.83 and last traded at $2.83. 300,636 shares traded hands during trading, a decline of 70% from the average session volume of 990,237 shares. The stock had previously closed at $2.70. Analyst Ratings Changes A number […] ....

Montreal , Quebec , Canada , United-states , American , Amneal-pharmaceuticals-inc , Institutional-trading-of-amneal-pharmaceuticals , Pricet-rowe-associates-inc , News-ratings-for-amneal-pharmaceuticals-daily , Grantham-mayo-van-otterloo-co , Amneal-pharmaceuticals-stock-performance